세계의 mRNA 합성 및 제조 시장 예측(-2029년) : 제품별, 용도별, 최종사용자별, 서비스별, 지역별

mRNA Synthesis & Manufacturing Market by Product (Consumables [Transcription, Purification, Analysis & Characterization], Instrument), Service (Synthesis, Purification, Manufacturing & Scale-up), Application (CGT, Vaccines) - Global Forecast to 2029

US $ 4,950 ￦ 6,896,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,265,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,355,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,933,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

mRNA 합성·제조 시장 규모는 2024년 6억 2,440만 달러에서 2029년에는 7억 3,830만 달러에 달할 것으로 예측되고 있으며, 예측 기간 중 CAGR은 3.4%에 달할 것으로 보이고 있습니다.

mRNA 치료제는 재생의학에서 조직 복구를 위한 차세대 약물로 유망한 것으로 평가받고 있습니다. 비면역원성 mRNA의 개발은 안전성과 효능을 향상시키는 변형된 뉴클레오시드를 사용하여 달성할 수 있으며, mRNA의 구조를 변화시킴으로써 연구자들은 in vitro 전사를 통해 안정적인 비면역원성 mRNA를 생성할 수 있습니다. 또한 mRNA에 특화된 효과적인 전달 전략은 이러한 치료법의 발전에 필수적입니다. 생체 재료에서 mRNA를 적재하고 방출하는 과정은 조직 복구에 적용하기 위해 필수적이며, 그 잠재력을 극대화하기 위해서는 더 많은 개선이 필요합니다.

조사 범위
조사 대상연도	2022-2029년
기준연도	2023년
예측 기간	2024-2029년
검토 단위	금액(100만 달러)
부문별	제품별, 용도별, 최종사용자별, 서비스별, 지역별
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

제품별로 mRNA 합성 및 제조 시장은 소모품, 장비로 구분되며, 소모품 부문은 2023년 mRNA 합성 및 제조 시장에서 가장 큰 점유율을 차지할 것으로 예상되며, 이 부문은 다시 전사 소모품, 정제 소모품, 분석 및 특성화 소모품으로 세분화됩니다. 소모품 부문이 예측 기간 중 우위를 점하는 이유는 mRNA 합성 및 제조에 필수적인 소모품이 일회성 투자인 장비와 달리 소모품은 주기적으로 보충해야 하므로 지속적인 수요가 발생하기 때문입니다. 또한 전체 시장은 주로 Thermo Fisher Scientific Inc.(미국), Sartorius AG(독일)가 제공하는 장비에 의해 운영되고 있지만, mRNA 합성 및 제조를 위한 소모품 분야에서는 더 많은 기업이 활동하고 있습니다.

서비스별로 mRNA 합성 및 제조 시장은 mRNA 합성 및 변형, mRNA 정제, mRNA 분석 및 특성화, 제조 및 스케일업으로 구분되며, 2023년 mRNA 합성 및 제조 시장에서 mRNA 합성 및 변형 분야가 가장 큰 점유율을 차지할 것으로 예상됩니다. mRNA 합성 및 변형 서비스의 중요한 촉진요인은 치료제 및 백신 후보물질의 효능과 안정성을 높이기 위해 맞춤형 mRNA 서열 및 변형의 필요성이 증가하고 있으며, 이를 위해서는 전문적인 합성 및 변형 서비스가 필요하다는 점입니다. 연구자 및 개발자들은 단백질 발현 개선, 면역 반응 강화 등 특정 치료 효과에 최적화할 수 있는 맞춤형 mRNA 서열을 요구하고 있습니다.

아시아태평양은 전 세계 mRNA 합성 및 제조 시장에서 가장 빠르게 성장하는 지역입니다. 의료비 증가, 인도, 중국, 일본 등 주요 시장에서의 연구개발 확대, 낮은 인건비, 양호한 규제 환경 등의 요인이 시장 성장에 기여할 것으로 예상됩니다. 중국의 mRNA 합성 및 제조 시장은 바이오 기술 혁신에 대한 정부의 막대한 투자, 국내 바이오 기술 인프라의 급속한 확장, 국제 협력 관계 증가에 의해 주도되고 있습니다. 최근 중국은 mRNA 기술 발전에 대한 강한 의지를 보이고 있습니다.

세계의 mRNA 합성·제조 시장에 대해 조사했으며, 제품별, 용도별, 최종사용자별, 서비스별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 주요 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 고객 비즈니스에 영향을 미치는 동향/혼란
• 규제 상황
• 밸류체인 분석
• 기술 분석
• 가격 분석
• 특허 분석
• 공급망 분석
• 에코시스템 분석
• 2025-2026년의 주요 컨퍼런스와 이벤트
• Porter's Five Forces 분석
• 주요 이해관계자와 구입 기준
• 투자와 자금조달 시나리오
• AI가 mRNA 합성·제조 시장에 미치는 영향

제6장 mRNA 합성·제조 시장(제품별)

• 서론
• 소모품
• 기기

제7장 mRNA 합성·제조 제품 시장(용도별)

• 서론
• 세포·유전자 치료
• 백신
• 기타

제8장 mRNA 합성·제조 제품 시장(최종사용자별)

• 서론
• 제약·바이오테크놀러지 기업
• 학술·연구기관
• CRO·CDMO

제9장 mRNA 합성·제조 시장(서비스별)

• 서론
• mRNA 합성 및 수식 서비스
• mRNA 정제 서비스
• mRNA 분석 및 특성 평가 서비스
• 제조 및 스케일 업 서비스

제10장 mRNA 합성·제조 서비스 시장(최종사용자별)

• 서론
• 제약·바이오테크놀러지 기업
• 학술·연구기관
• 소규모 CRO 및 CDMO

제11장 mRNA 합성·제조 시장(지역별)

• 서론
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시경제 전망
  • 독일
  • 영국
  • 프랑스
  • 스위스
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 아시아태평양의 거시경제 전망
  • 중국
  • 일본
  • 인도
  • 한국
  • 기타
• 라틴아메리카
  • 라틴아메리카의 거시경제 전망
  • 브라질
  • 기타
• 중동
  • 민간 부문과 학술 조사 구상으로부터의 투자 증가가 시장을 촉진
  • 중동의 거시경제 전망
• 아프리카
  • 시장 확대를 위해 현지 생산능력을 강화하는 구상이 확대
  • 아프리카의 거시경제 전망

제13장 기업 개요

• 주요 참여 기업
  • THERMO FISHER SCIENTIFIC INC.
  • DANAHER CORPORATION
  • MERCK KGAA
  • LONZA
  • MARVAI LIFESCIENCES
  • GENSCRIPT
  • NEW ENGLAND BIOLABS
  • PROMEGA CORPORATION
  • WUXI BIOLOGICS
  • TAKARA BIO INC.
  • SARTORIUS AG
  • AZENTA US INC.
  • TELESIS BIO INC.
  • ST PHARM
  • AGC INC.(THROUGH AGC BIOLOGICS)
  • DR. REDDY'S LABORATORIES LTD.
• 기타 기업
  • ETHERNA
  • BOC SCIENCES
  • BIOMAY AG
  • CURIA GLOBAL, INC.
  • JENA BIOSCIENCE GMBH
  • ENZYNOMICS CO., LTD.
  • KANEKA EUROGENTEC S.A.
  • VERNAL BIOSCIENCES
  • CELLSCRIPT

제14장 부록

KSA

영문 목차

영문목차

The mRNA synthesis and manufacturing market is expected to reach USD 738.3 million in 2029 from USD 624.4 million in 2024, at a CAGR of 3.4% during the forecast period. mRNA therapeutics hold promise as the next generation of drugs for tissue restoration in regenerative medicine. The development of non-immunogenic mRNA can be achieved through the use of modified nucleosides, which enhances safety and efficacy. By altering the mRNA structure, researchers can create stable, non-immunogenic mRNA through in vitro transcription. Furthermore, effective delivery strategies tailored specifically for mRNA are crucial for the advancement of these therapies. The processes involved in loading and releasing mRNA from biomaterials are essential for their application in tissue restoration and require further refinement to maximize their potential.

Scope of the Report
Years Considered for the Study	2022-2029
Base Year	2023
Forecast Period	2024-2029
Units Considered	Value (USD Million)
Segments	By Product, Application, Service, and End Users
Regions covered	North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

"The transcription consumables segment accounted for the largest share by product segment in the mRNA synthesis and manufacturing market in 2023."

Based on product, the mRNA synthesis and manufacturing market is segmented into consumables, and instrument. In 2023, the consumables segment accounted for the largest share of mRNA synthesis and manufacturing market; this segment is further segmented into transcription consumables, purification consumables, and analysis & characterization consumables. Dominance of the consumables segment throughout the forecast period is attributed to the fact that they are essential for mRNA synthesis and manufacturing. Unlike instruments, which are a one-time investment, consumables must be replenished regularly, leading to continuous demand. Also, the entire market operates majorly on instruments offered by Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), whereas more companies operate in the consumables space for mRNA synthesis and manufacturing.

"The mRNA synthesis & modification service segment is expected to grow at the highest growth rate in the mRNA synthesis and manufacturing market throughout the forecast period."

Based on service, the mRNA synthesis and manufacturing market is segmented into mRNA synthesis & modification, mRNA purification, mRNA analysis & characterization, and manufacturing & scale-up. In 2023, the mRNA synthesis & modification segment accounted for the largest share of the mRNA synthesis and manufacturing market. A significant driver for the mRNA synthesis and modification services within the mRNA synthesis and manufacturing market is the growing need for customized mRNA sequences and modifications to enhance the efficacy and stability of therapeutic and vaccine candidates, which requires specialized synthesis and modification services. As the application of mRNA technology expands, researchers and developers increasingly seek tailored mRNA sequences that can be optimized for specific therapeutic outcomes, such as improved protein expression or enhanced immune response.

"The Asia Pacific region is growing at the highest CAGR in the mRNA synthesis and manufacturing market from 2024 to 2029."

The mRNA synthesis and manufacturing market is segmented into six major regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific is the fastest-growing regional segment in the global mRNA synthesis and manufacturing market, Factors such as rising healthcare expenditure; growing R&D expansion in key markets such as India, China, and Japan; low labor costs; and the favorable regulatory environment in the region are expected to contribute to market growth. China's mRNA synthesis and manufacturing market is driven by the country's substantial government investments in biotech innovation, rapid expansion of domestic biotech infrastructure, and increasing international collaborations. In recent developments, China has demonstrated a strong commitment to advancing mRNA technology.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
• By Designation: Directors - 50%, Managers - 30%, and Others - 20%
• By Region: North America -40%, Europe -35%, Asia-Pacific -20%, ROW -5%

List of Companies Profiled in the Report:

• Merck KGaA (Germany)
• Thermo Fisher Scientific Inc. (US)
• GenScript (US)
• New England Biolabs (US)
• AldevronLLC. (Danaher Corporation) (US)
• Promega Corporation (US)
• Sartorius AG (Germany)
• WuXi Biologics (China)
• Takara Bio Inc. (Japan)
• GENEWIZ (Azenta USInc.) (US)
• TriLink BioTechnologies (US)
• Lonza (Switzerland)
• Telesis Bio Inc. (US)
• Aurigene Pharmaceutical Services Ltd. (Dr. Reddy's Laboratories Ltd.) (India)
• ST Pharm (South Korea)AGC Biologics (US)

Research Coverage:

This research report categorizes the mRNA synthesis and manufacturing market by Product (transcription consumables, purification consumables, analysis & characterization consumables, and instrument), Application (cell and gene therapy, vaccine, and other applications), End User (pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the mRNA synthesis and manufacturing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the mRNA synthesis and manufacturing market. Competitive analysis of top players and upcoming startups in the mRNA synthesis and manufacturing market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall mRNA synthesis and manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing focus on mRNA-based vaccine development, expanding therapeutic applications of mrna technology, advancements in mrna synthesis technology, increased outsourcing for mrna synthesis and modification, and collaborations among industry players), restraints (High production cost, stringent regulations), opportunities (Advancements in drug delivery technologies, increased government funding and private investment, applications in regenerative medicines), and challenges (Stability, storage, and manufacturing scalability) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the mRNA synthesis and manufacturing market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the mRNA synthesis and manufacturing market
• Competitive Assessment: Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), GenScript (US), New England Biolabs (US), Aldevron, LLC. (Danaher Corporation) (US), Promega Corporation (US), Sartorius AG (Germany), WuXi Biologics (China), Takara Bio Inc. (Japan), GENEWIZ (Azenta US, Inc.) (US), TriLink BioTechnologies (US), Lonza (Switzerland), Telesis Bio Inc. (US), Aurigene Pharmaceutical Services Ltd. (Dr. Reddy's Laboratories Ltd.) (India), ST Pharm (South Korea), AGC Biologics (US), among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET SIZE ESTIMATION
  • 2.2.2 INSIGHTS FROM PRIMARY SOURCES
  • 2.2.3 TOP-DOWN APPROACH
• 2.3 GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 MRNA SYNTHESIS & MANUFACTURING MARKET OVERVIEW
• 4.2 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT AND COUNTRY, 2023
• 4.3 MRNA SYNTHESIS & MANUFACTURING SERVICES MARKET: GLOBAL GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rise in clinical trials for mRNA vaccines
    • 5.2.1.2 Continuous improvements in design, delivery systems, and manufacturing processes
    • 5.2.1.3 Increased outsourcing of mRNA synthesis and production
    • 5.2.1.4 Advantages of mRNA-based technology over recombinant expression
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High production cost
    • 5.2.2.2 Stringent regulations
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Ongoing innovations in nanoparticles and cell-specific delivery technologies
    • 5.2.3.2 Expanding applications of mRNA technology
    • 5.2.3.3 Increased government funding and private investments
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stability, storage, and manufacturing scalability issues
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 REGULATORY LANDSCAPE
  • 5.4.1 REGULATORY FRAMEWORK
  • 5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 TECHNOLOGY ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 In vitro transcription
    • 5.6.1.2 Poly(A) tail synthesis
    • 5.6.1.3 RNA stabilization technologies
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 Next-generation sequencing
    • 5.6.2.2 Gene cloning and vector construction
    • 5.6.2.3 DNA amplification
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Spectrophotometry
    • 5.6.3.2 Electrophoresis
    • 5.6.3.3 High-performance liquid chromatography
• 5.7 PRICING ANALYSIS
  • 5.7.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY INSTRUMENT
  • 5.7.2 AVERAGE SELLING PRICE TREND FOR CONSUMABLES
  • 5.7.3 AVERAGE SELLING PRICE, BY REGION
• 5.8 PATENT ANALYSIS
• 5.9 SUPPLY CHAIN ANALYSIS
• 5.10 ECOSYSTEM ANALYSIS
• 5.11 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12.2 BARGAINING POWER OF SUPPLIERS
  • 5.12.3 BARGAINING POWER OF BUYERS
  • 5.12.4 THREAT OF SUBSTITUTES
  • 5.12.5 THREAT OF NEW ENTRANTS
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 KEY BUYING CRITERIA, BY END USER (PRODUCT)
• 5.14 INVESTMENT AND FUNDING SCENARIO
• 5.15 IMPACT OF AI ON MRNA SYNTHESIS & MANUFACTURING MARKET

6 MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 TRANSCRIPTION CONSUMABLES
    • 6.2.1.1 mRNA synthesis kits
      • 6.2.1.1.1 Increasing demand for rapid and efficient mRNA vaccine development to augment growth
    • 6.2.1.2 mRNA profiling kits
      • 6.2.1.2.1 Growing need for precision medicine and personalized therapies to propel market
    • 6.2.1.3 RNA polymerases
      • 6.2.1.3.1 Growing demand for high-quality and scalable mRNA production to boost market
    • 6.2.1.4 Plasmid DNA/DNA templates
      • 6.2.1.4.1 Rapid growth of mRNA-based therapeutics and vaccines to expedite growth
    • 6.2.1.5 Nucleotides
      • 6.2.1.5.1 Need to support diverse research & development initiatives to promote growth
    • 6.2.1.6 Vectors
      • 6.2.1.6.1 Need for reliable and high-capacity vectors to propel market
    • 6.2.1.7 Other transcription consumables
  • 6.2.2 PURIFICATION CONSUMABLES
    • 6.2.2.1 Purification kits & reagents
      • 6.2.2.1.1 Rising focus on quality assurance to encourage growth
    • 6.2.2.2 Chromatography filters & membranes
      • 6.2.2.2.1 Growing emphasis on process optimization and cost-efficiency in large-scale production to drive market
    • 6.2.2.3 Other purification consumables
  • 6.2.3 ANALYSIS & CHARACTERIZATION CONSUMABLES
    • 6.2.3.1 Analysis kits & reagents
      • 6.2.3.1.1 Emerging applications of mRNA beyond vaccines to support growth
    • 6.2.3.2 Other analysis & characterization consumables
• 6.3 INSTRUMENTS
  • 6.3.1 NEED TO REDUCE PRODUCTION COST AND HIGHER SCALABILITY TO PROMOTE GROWTH

7 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 CELL & GENE THERAPIES
  • 7.2.1 RISING ADOPTION OF MRNA TECHNOLOGY TO TREAT GENETIC DISORDERS AND CANCER TO FUEL MARKET
• 7.3 VACCINES
  • 7.3.1 INCREASING DEVELOPMENT AND DEPLOYMENT OF MRNA VACCINES TO ACCELERATE GROWTH
• 7.4 OTHER APPLICATIONS

8 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 8.2.1 NEED TO RESPOND TO EMERGING INFECTIOUS DISEASES TO DRIVE MARKET
• 8.3 ACADEMIC & RESEARCH INSTITUTIONS
  • 8.3.1 INCREASING INVESTMENTS IN RESEARCH TO EXPEDITE GROWTH
• 8.4 CROS & CDMOS
  • 8.4.1 RISING DEMAND FOR OUTSOURCED SERVICES TO AID GROWTH

9 MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE

• 9.1 INTRODUCTION
• 9.2 MRNA SYNTHESIS & MODIFICATION SERVICES
  • 9.2.1 GROWING NEED FOR CUSTOMIZED MRNA SEQUENCES AND MODIFICATIONS TO FUEL MARKET
• 9.3 MRNA PURIFICATION SERVICES
  • 9.3.1 NEED FOR PERSONALIZED MRNA VACCINES TO BOOST MARKET
• 9.4 MRNA ANALYSIS & CHARACTERIZATION SERVICES
  • 9.4.1 INCREASING REGULATORY SCRUTINY TO EXPEDITE GROWTH
• 9.5 MANUFACTURING & SCALE-UP SERVICES
  • 9.5.1 GROWING TRANSITION FROM SMALL-SCALE RESEARCH & DEVELOPMENT TO LARGE-SCALE COMMERCIAL PRODUCTION TO DRIVE MARKET

10 MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 RAPID DEVELOPMENT AND COMMERCIALIZATION OF MRNA-BASED PRODUCTS TO ENCOURAGE GROWTH
• 10.3 ACADEMIC & RESEARCH INSTITUTIONS
  • 10.3.1 INCREASING EMPHASIS ON TRANSLATING MRNA-BASED DISCOVERIES INTO PRACTICAL APPLICATIONS TO AID GROWTH
• 10.4 SMALL-SCALE CROS & CDMOS
  • 10.4.1 NEED FOR SPECIALIZED AND FLEXIBLE PRODUCTION IN BIOTECH COMPANIES AND EARLY-STAGE MRNA PROJECTS TO BOOST MARKET

11 MRNA SYNTHESIS & MANUFACTURING MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Increasing demand for mRNA-based vaccines and therapeutics to accelerate growth
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing collaborations between academic institutions and market players to spur growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Growing establishment of manufacturing sites to boost market
  • 11.3.3 UK
    • 11.3.3.1 Presence of state-of-the-art facilities to support growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Favorable government support for biopharmaceutical production to drive market
  • 11.3.5 SWITZERLAND
    • 11.3.5.1 Robust biotech sector and production facilities to promote growth
  • 11.3.6 ITALY
    • 11.3.6.1 Increasing collaborations among biotech firms and manufacturing facilities to aid growth
  • 11.3.7 SPAIN
    • 11.3.7.1 Growing investments in biotechnology to fuel market
  • 11.3.8 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Rapid expansion of domestic biotech sector to contribute to growth
  • 11.4.3 JAPAN
    • 11.4.3.1 Growing strategic investments in biotechnology infrastructure to boost market
  • 11.4.4 INDIA
    • 11.4.4.1 Booming biotech sector and international collaborations to augment growth
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 Increased government funding in research and vaccine development to bolster growth
  • 11.4.6 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Increased funding for strengthening infrastructure to sustain growth
  • 11.5.3 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 GROWING INVESTMENTS FROM PRIVATE SECTOR AND ACADEMIC RESEARCH INITIATIVES TO DRIVE MARKET
  • 11.6.2 MACROECONOMIC OUTLOOK IN MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 GROWING INITIATIVES TO ENHANCE LOCAL PRODUCTION CAPABILITIES TO PROPEL MARKET
  • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 THERMO FISHER SCIENTIFIC INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product/Service launches
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 DANAHER CORPORATION
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product/Service launches
      • 13.1.2.3.2 Deals
      • 13.1.2.3.3 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 MERCK KGAA
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
      • 13.1.3.3.2 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 LONZA
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
      • 13.1.4.3.2 Expansions
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses and competitive threats
  • 13.1.5 MARVAI LIFESCIENCES
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product/Service launches
      • 13.1.5.3.2 Deals
      • 13.1.5.3.3 Expansions
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses and competitive threats
  • 13.1.6 GENSCRIPT
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product/Service launches
      • 13.1.6.3.2 Deals
      • 13.1.6.3.3 Expansions
    • 13.1.6.4 MnM view
      • 13.1.6.4.1 Key strengths
      • 13.1.6.4.2 Strategic choices
      • 13.1.6.4.3 Weaknesses and competitive threats
  • 13.1.7 NEW ENGLAND BIOLABS
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product/Service launches
  • 13.1.8 PROMEGA CORPORATION
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Expansions
      • 13.1.8.3.2 Other developments
  • 13.1.9 WUXI BIOLOGICS
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Expansions
  • 13.1.10 TAKARA BIO INC.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Product/Service launches
      • 13.1.10.3.2 Deals
  • 13.1.11 SARTORIUS AG
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/Services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Deals
  • 13.1.12 AZENTA US INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services offered
  • 13.1.13 TELESIS BIO INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products/Services offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product/Service launches
      • 13.1.13.3.2 Deals
  • 13.1.14 ST PHARM
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products/Services offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Deals
  • 13.1.15 AGC INC. (THROUGH AGC BIOLOGICS)
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products/Services offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Deals
      • 13.1.15.3.2 Expansions
  • 13.1.16 DR. REDDY'S LABORATORIES LTD.
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products/Services offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Expansions
• 13.2 OTHER PLAYERS
  • 13.2.1 ETHERNA
  • 13.2.2 BOC SCIENCES
  • 13.2.3 BIOMAY AG
  • 13.2.4 CURIA GLOBAL, INC.
  • 13.2.5 JENA BIOSCIENCE GMBH
  • 13.2.6 ENZYNOMICS CO., LTD.
  • 13.2.7 KANEKA EUROGENTEC S.A.
  • 13.2.8 VERNAL BIOSCIENCES
  • 13.2.9 CELLSCRIPT

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

관련자료